The company believes that its DLL3-targeting ADC could be fast-tracked despite the presence of Imdelltra.

The fate of the group’s previous lead project, the Amgen-partnered CX-904, looks uncertain.

The synthetic lethality specialist licenses in its second ADC in six months.

Investors will hope for a JP Morgan buying spree, while readouts could come from Kura, Allogene and MacroGenics.

The company reports an “unprecedented” 100% PSA50 rate with JANX007, but in a small, selected number of patients.

Amid a KRAS data dump, a doublet of RMC-6236 and RMC-6291 was a highlight.

The company abandons TNG908, but is still all in on the troubled target.

October's US approvals included Scemblix, Vyloy and Itovebi, while Lumakras was delayed.

ZL-1310 looks better than other DLL3-targeting agents, but two thirds of responses are so far unconfirmed.